LJUBLJANA, SLOVENIA -- Cosylab and Heron Neutron Medical Corp. announced, 10 June 2026, the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems.

The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT’s international market access and business development. By combining Cosylab’s proven expertise in mission-critical software and complex system integration with Heron’s end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality.

“AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers,” said Mark Pleško, Chief Executive Officer of Cosylab. “This collaboration reinforces our strategic focus on advancing radiation therapy technologies and expanding our reach in the Asia-Pacific region and beyond. We are committed to delivering impactful joint projects with Heron that accelerate market readiness and clinical adoption.”

“This agreement represents a key step in Heron’s international growth strategy,” underlined Shen Hsiao-Lien, General Manager of Heron Neutron Medical Corp. “Working with Cosylab will strengthen our cross-regional capabilities and support the rapid scaling of AB-BNCT solutions in markets worldwide.”